Latest from Sarah Cannon

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.
Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.
Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.
Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.
OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.
David R. Spigel, MD, discusses updates in lung cancer presented at the 2019 ESMO Congress.
Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.
Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses current treatments in ESR1-mutant breast cancer.
Publication Bottom Border
Border Publication